- Home
- ZLAB vs FULT Comparison
ZLAB vs FULT Comparison
Compare ZLAB & FULT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- FULT
- Stock Information
- Founded
- ZLAB 2013
- FULT 1882
- Country
- ZLAB China
- FULT United States
- Employees
- ZLAB N/A
- FULT N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- FULT Major Banks
- Sector
- ZLAB Health Care
- FULT Finance
- Exchange
- ZLAB Nasdaq
- FULT Nasdaq
- Market Cap
- ZLAB 3.4B
- FULT 3.9B
- IPO Year
- ZLAB 2017
- FULT N/A
- Fundamental
- Price
- ZLAB $33.78
- FULT $19.68
- Analyst Decision
- ZLAB Strong Buy
- FULT Hold
- Analyst Count
- ZLAB 3
- FULT 5
- Target Price
- ZLAB $55.00
- FULT $20.20
- AVG Volume (30 Days)
- ZLAB 752.8K
- FULT 994.8K
- Earning Date
- ZLAB 02-27-2025
- FULT 04-15-2025
- Dividend Yield
- ZLAB N/A
- FULT 3.60%
- EPS Growth
- ZLAB N/A
- FULT N/A
- EPS
- ZLAB N/A
- FULT 1.57
- Revenue
- ZLAB $355,748,000.00
- FULT $1,127,424,000.00
- Revenue This Year
- ZLAB $49.04
- FULT N/A
- Revenue Next Year
- ZLAB $46.80
- FULT $5.26
- P/E Ratio
- ZLAB N/A
- FULT $12.72
- Revenue Growth
- ZLAB 35.01
- FULT 9.68
- 52 Week Low
- ZLAB $13.48
- FULT $13.87
- 52 Week High
- ZLAB $36.60
- FULT $22.49
- Technical
- Relative Strength Index (RSI)
- ZLAB 79.95
- FULT 41.13
- Support Level
- ZLAB $30.61
- FULT $20.44
- Resistance Level
- ZLAB $33.00
- FULT $20.94
- Average True Range (ATR)
- ZLAB 1.32
- FULT 0.54
- MACD
- ZLAB 0.58
- FULT -0.08
- Stochastic Oscillator
- ZLAB 86.34
- FULT 14.02
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
About FULT Fulton Financial Corporation
Fulton Financial is a U.S.-based financial services holding company that operates in five states: Pennsylvania, Delaware, Maryland, New Jersey, and Virginia. It offers a range of consumer and commercial banking products and services, such as checking and savings deposit products and loan products. It offers consumer and commercial banking products and services, as well as wealth management products and services. The bank derives its revenue from non-interest income, led by its Wealth Management division.